▲ 12 r/HighTideInc
France Breaks Medical Cannabis Deadlock as Reimbursement Decree Filed for Legal Review
Next market for Remexian ?
u/WilliamBlack97AI — 3 days ago
u/WilliamBlack97AI
r/slavelabour r/stocks r/StockLaunchers r/WSBAfterHours r/trading212 r/Trading r/StockBreakouts r/100xpennystock r/ValueInvesting r/Shortsqueeze r/stockstobuytoday r/IndianStockMarket r/HighTideInc r/GME r/u_WilliamBlack97AI r/TheRaceTo1Million r/InvestmentEducation r/smallstreetbets r/BMNRInvestors r/HireaWriter r/Canadapennystocks r/TheRaceTo10Million r/financialmodelling r/Pennystock r/RobinHoodPennyStocks r/Wealthsimple_Penny r/wallstreet r/wallstreetportfolios r/trakstocks r/stocktwits r/wallstreetbets2 r/StockInvest r/WallStreetbetsELITE r/10xPennyStocks r/forhire r/TheRaceTo100K r/investing r/pennystocks r/InvestingandTrading r/Stocktradingalerts r/SmallCapStocks r/siliconvalley r/Stocks_Picks r/Nextech3Dai
▲ 23 r/HighTideInc
5th AMA with Raj Grover on 15th July , This is the post for Questions
The High Tide Inc subreddit is happy to announce that Raj Grover will be having an AMA with the sub once again for the 5th time!
To mark the milestone and mention that all users who comment on the AMA will be in a random prize draw for a prize
Thanks to Raj for his ongoing commitment and transparency; every question is welcome.
u/WilliamBlack97AI — 5 days ago
▲ 12 r/BMNRInvestors
Crypto's Best Days Are Still Ahead, Says Fundstrat's Tom Lee
youtu.beu/WilliamBlack97AI — 6 days ago
▲ 1 r/Stocks_Picks
Q2 Earnings call summary High Tide inc
SUMMARY :
Despite the seasonally weaker quarter, it was the company's best quarter, which speaks volumes about HITI's increased operating efficiency.
Gms on medical cannabis 27%
Key Strengths of High Tide's Q2 FY2026
1. Strong Revenue Growth
- Record revenue of CAD $179.3 million.
- Approximately 30% year-over-year growth, representing one of the strongest growth rates in recent quarters.
2. Accelerating EBITDA Growth
- Record Adjusted EBITDA of CAD $13.9 million.
- EBITDA increased by approximately 73% year over year, significantly outpacing revenue growth, which indicates improving operating leverage and efficiency.
3. Positive Net Income
- The company reported positive net income and positive earnings per share (EPS).
- In the cannabis industry, profitability remains a major challenge for many companies, making High Tide's continued profitability particularly noteworthy.
- Management expects sustainable NET INCOME
4. Positive Free Cash Flow
- High Tide generated positive free cash flow and strong operating cash flow.
- This reduces the need to raise capital through equity issuances, helping to limit shareholder dilution.
5. Germany Continues to Exceed Expectations
- German subsidiary Remexian Pharma GmbH generated a record CAD $31.6 million in revenue.
- Gross margin improved to 27%.
- Management stated that several internal targets were achieved roughly 90 days ahead of schedule.
6. Rapid Expansion of the Customer Base
- The Cabana Club loyalty program surpassed 2.65 million members, up 39% year over year.
- ELITE memberships exceeded 178,000, up 84% year over year.
- This growing membership ecosystem strengthens customer loyalty, improves data analytics capabilities, and enhances High Tide's competitive advantage in retail.
- The stated goal is to exceed 1 million elite members in the long term.
7. Significant Banking Support
- The company secured a new credit facility of up to CAD $40 million from Bank of Montreal.
- Access to financing from a major Canadian bank is an important signal of financial credibility and stability in the cannabis sector.
- This has led to an increase in institutional interest in the stock which will be reflected as the company's fundamentals continue to improve.
8. Market Leadership
- High Tide continues to hold approximately 12% of the Canadian cannabis retail market in the provinces where it operates.
- The company is also steadily gaining market share in the German medical cannabis market.
- Raj is targeting 20% market share in Germany and I personally believe 30% is achievable in the long term for several reasons.
Most Bullish Takeaways
If I had to identify nine most bullish developments from the quarter, they would be:
- 73% growth in Adjusted EBITDA, demonstrating strong operational execution.
- Remexian's 27% gross margin, showing that the German business is scaling successfully and profitably.
- The new CAD $40 million credit facility, which provides growth capital without diluting shareholders.
- SNDL will have to sell some of its assets because it has violated regulations for years, and I wouldn't be surprised if it had to pay a hefty fine for breaking the law for so long. These assets will be carefully evaluated by Hiti for purchase.
- Possible increase in the cap in Ontario from 150->300 which Raj calls "a dream come true" bringing the number of canna cabana shops +500, but we'll have to see how things evolve
- The medical branch is growing throughout Europe, a constantly growing market, where Raj intends to be the leader in every country in which it operates (Germany, UK to follow).
- GMS have reached an all-time high. Raj states that due to competition, they will shrink slightly in the medium term in order to gain market share, but thanks to initiatives such as increasing ELITE/WHITE LABEL inventory from the current 2% to 25%, GMS will exceed 30% in the long term, also driven by Remexian's improved efficiency.
- Raj has stated his intention to enter the US, but for now he's focused on the European medical market and I support that.
- He says there's no rush to pursue multiple objectives at once, but rather to focus on one market at a time, strengthen its position by positioning itself as a leader, and move on to the next.
Together, these results suggest that High Tide is evolving from a pure growth story into a profitable growth company, a transition that investors often reward with higher valuation multiples over time.
HITI is becoming the definition of non-stop execution and deserves more credit for this. Remexian's goal is clear: gain more market share to satisfy this insatiable and ever-growing demand, in order to reach 20-30% market share in the long term and then achieve pricing determination with a consequent increase in GMS and profitability.
Still think HITI is vastly undiscovered.
Despite an increase in CAPEX linked to the expansion, the company continues to generate FCF+ and expects to increase net income thanks to ongoing synergies.
Raj is carefully evaluating expansion into another jurisdiction (UK), choosing the right partner for the long term.
This looks more like short-term noise than a deterioration in fundamentals. Remexian’s expansion in Germany and the economies of scale enjoyed by Canna Cabana represent genuine, differentiating competitive advantages. As long as management continues to pursue its market share targets and secure future pricing power, the valuation gap should gradually narrow. Investing in HITI will certainly be volatile, but the current fundamentals are much healthier than the stock price suggests. What's needed is patience and faith in the story.
The UK is the European market that excites him the most.
The UK medical market appears more interesting than the German one because High Tide could own the entire chain (from production directly to the patient). This is the medical system in which it is structured, which makes it exciting and unique in some respects.
I might be biased because HITI is my largest position by a wide margin, but that’s not why I’m saying this. Execution here has simply been exceptional. The numbers speak for themselves, the customer wins speak for themselves, and the pace of announcements speaks for itself.
Every analyst covering the company has a Buy rating
Canaccord Genuity → Buy, Target $US 5.50
Haywood → Buy, Target $US 5.90
Roth → Buy, target $US 5.00
TD Cowen → Buy, target $6.5 CAD
ATB CAPITAL Target 7$CAD
u/WilliamBlack97AI — 9 days ago
Q2 Earnings call summary High Tide inc
SUMMARY :
Despite the seasonally weaker quarter, it was the company's best quarter, which speaks volumes about HITI's increased operating efficiency.
Gms on medical cannabis 27%
Key Strengths of High Tide's Q2 FY2026
1. Strong Revenue Growth
- Record revenue of CAD $179.3 million.
- Approximately 30% year-over-year growth, representing one of the strongest growth rates in recent quarters.
2. Accelerating EBITDA Growth
- Record Adjusted EBITDA of CAD $13.9 million.
- EBITDA increased by approximately 73% year over year, significantly outpacing revenue growth, which indicates improving operating leverage and efficiency.
3. Positive Net Income
- The company reported positive net income and positive earnings per share (EPS).
- In the cannabis industry, profitability remains a major challenge for many companies, making High Tide's continued profitability particularly noteworthy.
- Management expects sustainable NET INCOME
4. Positive Free Cash Flow
- High Tide generated positive free cash flow and strong operating cash flow.
- This reduces the need to raise capital through equity issuances, helping to limit shareholder dilution.
5. Germany Continues to Exceed Expectations
- German subsidiary Remexian Pharma GmbH generated a record CAD $31.6 million in revenue.
- Gross margin improved to 27%.
- Management stated that several internal targets were achieved roughly 90 days ahead of schedule.
6. Rapid Expansion of the Customer Base
- The Cabana Club loyalty program surpassed 2.65 million members, up 39% year over year.
- ELITE memberships exceeded 178,000, up 84% year over year.
- This growing membership ecosystem strengthens customer loyalty, improves data analytics capabilities, and enhances High Tide's competitive advantage in retail.
- The stated goal is to exceed 1 million elite members in the long term.
7. Significant Banking Support
- The company secured a new credit facility of up to CAD $40 million from Bank of Montreal.
- Access to financing from a major Canadian bank is an important signal of financial credibility and stability in the cannabis sector.
- This has led to an increase in institutional interest in the stock which will be reflected as the company's fundamentals continue to improve.
8. Market Leadership
- High Tide continues to hold approximately 12% of the Canadian cannabis retail market in the provinces where it operates.
- The company is also steadily gaining market share in the German medical cannabis market.
- Raj is targeting 20% market share in Germany and I personally believe 30% is achievable in the long term for several reasons.
Most Bullish Takeaways
If I had to identify nine most bullish developments from the quarter, they would be:
- 73% growth in Adjusted EBITDA, demonstrating strong operational execution.
- Remexian's 27% gross margin, showing that the German business is scaling successfully and profitably.
- The new CAD $40 million credit facility, which provides growth capital without diluting shareholders.
- SNDL will have to sell some of its assets because it has violated regulations for years, and I wouldn't be surprised if it had to pay a hefty fine for breaking the law for so long. These assets will be carefully evaluated by Hiti for purchase.
- Possible increase in the cap in Ontario from 150->300 which Raj calls "a dream come true" bringing the number of canna cabana shops +500, but we'll have to see how things evolve
- The medical branch is growing throughout Europe, a constantly growing market, where Raj intends to be the leader in every country in which it operates (Germany, UK to follow).
- GMS have reached an all-time high. Raj states that due to competition, they will shrink slightly in the medium term in order to gain market share, but thanks to initiatives such as increasing ELITE/WHITE LABEL inventory from the current 2% to 25%, GMS will exceed 30% in the long term, also driven by Remexian's improved efficiency.
- Raj has stated his intention to enter the US, but for now he's focused on the European medical market and I support that.
- He says there's no rush to pursue multiple objectives at once, but rather to focus on one market at a time, strengthen its position by positioning itself as a leader, and move on to the next.
Together, these results suggest that High Tide is evolving from a pure growth story into a profitable growth company, a transition that investors often reward with higher valuation multiples over time.
HITI is becoming the definition of non-stop execution and deserves more credit for this. Remexian's goal is clear: gain more market share to satisfy this insatiable and ever-growing demand, in order to reach 20-30% market share in the long term and then achieve pricing determination with a consequent increase in GMS and profitability.
Still think HITI is vastly undiscovered.
Despite an increase in CAPEX linked to the expansion, the company continues to generate FCF+ and expects to increase net income thanks to ongoing synergies.
Raj is carefully evaluating expansion into another jurisdiction (UK), choosing the right partner for the long term.
This looks more like short-term noise than a deterioration in fundamentals. Remexian’s expansion in Germany and the economies of scale enjoyed by Canna Cabana represent genuine, differentiating competitive advantages. As long as management continues to pursue its market share targets and secure future pricing power, the valuation gap should gradually narrow. Investing in HITI will certainly be volatile, but the current fundamentals are much healthier than the stock price suggests. What's needed is patience and faith in the story.
The UK is the European market that excites him the most.
The UK medical market appears more interesting than the German one because High Tide could own the entire chain (from production directly to the patient). This is the medical system in which it is structured, which makes it exciting and unique in some respects.
I might be biased because HITI is my largest position by a wide margin, but that’s not why I’m saying this. Execution here has simply been exceptional. The numbers speak for themselves, the customer wins speak for themselves, and the pace of announcements speaks for itself.
Every analyst covering the company has a Buy rating
Canaccord Genuity → Buy, Target $US 5.50
Haywood → Buy, Target $US 5.90
Roth → Buy, target $US 5.00
TD Cowen → Buy, target $6.5 CAD
ATB CAPITAL Target 7$CAD
u/WilliamBlack97AI — 9 days ago
▲ 2 r/pennystocks
Q2 Earnings call summary High Tide inc
SUMMARY :
Despite the seasonally weaker quarter, it was the company's best quarter, which speaks volumes about HITI's increased operating efficiency.
Gms on medical cannabis 27%
Key Strengths of High Tide's Q2 FY2026
1. Strong Revenue Growth
- Record revenue of CAD $179.3 million.
- Approximately 30% year-over-year growth, representing one of the strongest growth rates in recent quarters.
2. Accelerating EBITDA Growth
- Record Adjusted EBITDA of CAD $13.9 million.
- EBITDA increased by approximately 73% year over year, significantly outpacing revenue growth, which indicates improving operating leverage and efficiency.
3. Positive Net Income
- The company reported positive net income and positive earnings per share (EPS).
- In the cannabis industry, profitability remains a major challenge for many companies, making High Tide's continued profitability particularly noteworthy.
- Management expects sustainable NET INCOME
4. Positive Free Cash Flow
- High Tide generated positive free cash flow and strong operating cash flow.
- This reduces the need to raise capital through equity issuances, helping to limit shareholder dilution.
5. Germany Continues to Exceed Expectations
- German subsidiary Remexian Pharma GmbH generated a record CAD $31.6 million in revenue.
- Gross margin improved to 27%.
- Management stated that several internal targets were achieved roughly 90 days ahead of schedule.
6. Rapid Expansion of the Customer Base
- The Cabana Club loyalty program surpassed 2.65 million members, up 39% year over year.
- ELITE memberships exceeded 178,000, up 84% year over year.
- This growing membership ecosystem strengthens customer loyalty, improves data analytics capabilities, and enhances High Tide's competitive advantage in retail.
- The stated goal is to exceed 1 million elite members in the long term.
7. Significant Banking Support
- The company secured a new credit facility of up to CAD $40 million from Bank of Montreal.
- Access to financing from a major Canadian bank is an important signal of financial credibility and stability in the cannabis sector.
- This has led to an increase in institutional interest in the stock which will be reflected as the company's fundamentals continue to improve.
8. Market Leadership
- High Tide continues to hold approximately 12% of the Canadian cannabis retail market in the provinces where it operates.
- The company is also steadily gaining market share in the German medical cannabis market.
- Raj is targeting 20% market share in Germany and I personally believe 30% is achievable in the long term for several reasons.
Most Bullish Takeaways
If I had to identify nine most bullish developments from the quarter, they would be:
- 73% growth in Adjusted EBITDA, demonstrating strong operational execution.
- Remexian's 27% gross margin, showing that the German business is scaling successfully and profitably.
- The new CAD $40 million credit facility, which provides growth capital without diluting shareholders.
- SNDL will have to sell some of its assets because it has violated regulations for years, and I wouldn't be surprised if it had to pay a hefty fine for breaking the law for so long. These assets will be carefully evaluated by Hiti for purchase.
- Possible increase in the cap in Ontario from 150->300 which Raj calls "a dream come true" bringing the number of canna cabana shops +500, but we'll have to see how things evolve
- The medical branch is growing throughout Europe, a constantly growing market, where Raj intends to be the leader in every country in which it operates (Germany, UK to follow).
- GMS have reached an all-time high. Raj states that due to competition, they will shrink slightly in the medium term in order to gain market share, but thanks to initiatives such as increasing ELITE/WHITE LABEL inventory from the current 2% to 25%, GMS will exceed 30% in the long term, also driven by Remexian's improved efficiency.
- Raj has stated his intention to enter the US, but for now he's focused on the European medical market and I support that.
- He says there's no rush to pursue multiple objectives at once, but rather to focus on one market at a time, strengthen its position by positioning itself as a leader, and move on to the next.
Together, these results suggest that High Tide is evolving from a pure growth story into a profitable growth company, a transition that investors often reward with higher valuation multiples over time.
HITI is becoming the definition of non-stop execution and deserves more credit for this. Remexian's goal is clear: gain more market share to satisfy this insatiable and ever-growing demand, in order to reach 20-30% market share in the long term and then achieve pricing determination with a consequent increase in GMS and profitability.
Still think HITI is vastly undiscovered.
Despite an increase in CAPEX linked to the expansion, the company continues to generate FCF+ and expects to increase net income thanks to ongoing synergies.
Raj is carefully evaluating expansion into another jurisdiction (UK), choosing the right partner for the long term.
This looks more like short-term noise than a deterioration in fundamentals. Remexian’s expansion in Germany and the economies of scale enjoyed by Canna Cabana represent genuine, differentiating competitive advantages. As long as management continues to pursue its market share targets and secure future pricing power, the valuation gap should gradually narrow. Investing in HITI will certainly be volatile, but the current fundamentals are much healthier than the stock price suggests. What's needed is patience and faith in the story.
The UK is the European market that excites him the most.
The UK medical market appears more interesting than the German one because High Tide could own the entire chain (from production directly to the patient). This is the medical system in which it is structured, which makes it exciting and unique in some respects.
I might be biased because HITI is my largest position by a wide margin, but that’s not why I’m saying this. Execution here has simply been exceptional. The numbers speak for themselves, the customer wins speak for themselves, and the pace of announcements speaks for itself.
Every analyst covering the company has a Buy rating
Canaccord Genuity → Buy, Target $US 5.50
Haywood → Buy, Target $US 5.90
Roth → Buy, target $US 5.00
TD Cowen → Buy, target $6.5 CAD
ATB CAPITAL Target 7$CAD
company presentation
https://hightideinc.com/presentation/
Long term
u/WilliamBlack97AI — 9 days ago
Q2 Earnings call summary High Tide inc
SUMMARY :
Despite the seasonally weaker quarter, it was the company's best quarter, which speaks volumes about HITI's increased operating efficiency.
Gms on medical cannabis 27%
Key Strengths of High Tide's Q2 FY2026
1. Strong Revenue Growth
- Record revenue of CAD $179.3 million.
- Approximately 30% year-over-year growth, representing one of the strongest growth rates in recent quarters.
2. Accelerating EBITDA Growth
- Record Adjusted EBITDA of CAD $13.9 million.
- EBITDA increased by approximately 73% year over year, significantly outpacing revenue growth, which indicates improving operating leverage and efficiency.
3. Positive Net Income
- The company reported positive net income and positive earnings per share (EPS).
- In the cannabis industry, profitability remains a major challenge for many companies, making High Tide's continued profitability particularly noteworthy.
- Management expects sustainable NET INCOME
4. Positive Free Cash Flow
- High Tide generated positive free cash flow and strong operating cash flow.
- This reduces the need to raise capital through equity issuances, helping to limit shareholder dilution.
5. Germany Continues to Exceed Expectations
- German subsidiary Remexian Pharma GmbH generated a record CAD $31.6 million in revenue.
- Gross margin improved to 27%.
- Management stated that several internal targets were achieved roughly 90 days ahead of schedule.
6. Rapid Expansion of the Customer Base
- The Cabana Club loyalty program surpassed 2.65 million members, up 39% year over year.
- ELITE memberships exceeded 178,000, up 84% year over year.
- This growing membership ecosystem strengthens customer loyalty, improves data analytics capabilities, and enhances High Tide's competitive advantage in retail.
- The stated goal is to exceed 1 million elite members in the long term.
7. Significant Banking Support
- The company secured a new credit facility of up to CAD $40 million from Bank of Montreal.
- Access to financing from a major Canadian bank is an important signal of financial credibility and stability in the cannabis sector.
- This has led to an increase in institutional interest in the stock which will be reflected as the company's fundamentals continue to improve.
8. Market Leadership
- High Tide continues to hold approximately 12% of the Canadian cannabis retail market in the provinces where it operates.
- The company is also steadily gaining market share in the German medical cannabis market.
- Raj is targeting 20% market share in Germany and I personally believe 30% is achievable in the long term for several reasons.
Most Bullish Takeaways
If I had to identify nine most bullish developments from the quarter, they would be:
- 73% growth in Adjusted EBITDA, demonstrating strong operational execution.
- Remexian's 27% gross margin, showing that the German business is scaling successfully and profitably.
- The new CAD $40 million credit facility, which provides growth capital without diluting shareholders.
- SNDL will have to sell some of its assets because it has violated regulations for years, and I wouldn't be surprised if it had to pay a hefty fine for breaking the law for so long. These assets will be carefully evaluated by Hiti for purchase.
- Possible increase in the cap in Ontario from 150->300 which Raj calls "a dream come true" bringing the number of canna cabana shops +500, but we'll have to see how things evolve
- The medical branch is growing throughout Europe, a constantly growing market, where Raj intends to be the leader in every country in which it operates (Germany, UK to follow).
- GMS have reached an all-time high. Raj states that due to competition, they will shrink slightly in the medium term in order to gain market share, but thanks to initiatives such as increasing ELITE/WHITE LABEL inventory from the current 2% to 25%, GMS will exceed 30% in the long term, also driven by Remexian's improved efficiency.
- Raj has stated his intention to enter the US, but for now he's focused on the European medical market and I support that.
- He says there's no rush to pursue multiple objectives at once, but rather to focus on one market at a time, strengthen its position by positioning itself as a leader, and move on to the next.
Together, these results suggest that High Tide is evolving from a pure growth story into a profitable growth company, a transition that investors often reward with higher valuation multiples over time.
HITI is becoming the definition of non-stop execution and deserves more credit for this. Remexian's goal is clear: gain more market share to satisfy this insatiable and ever-growing demand, in order to reach 20-30% market share in the long term and then achieve pricing determination with a consequent increase in GMS and profitability.
Still think HITI is vastly undiscovered.
Despite an increase in CAPEX linked to the expansion, the company continues to generate FCF+ and expects to increase net income thanks to ongoing synergies.
Raj is carefully evaluating expansion into another jurisdiction (UK), choosing the right partner for the long term.
This looks more like short-term noise than a deterioration in fundamentals. Remexian’s expansion in Germany and the economies of scale enjoyed by Canna Cabana represent genuine, differentiating competitive advantages. As long as management continues to pursue its market share targets and secure future pricing power, the valuation gap should gradually narrow. Investing in HITI will certainly be volatile, but the current fundamentals are much healthier than the stock price suggests. What's needed is patience and faith in the story.
The UK is the European market that excites him the most.
The UK medical market appears more interesting than the German one because High Tide could own the entire chain (from production directly to the patient). This is the medical system in which it is structured, which makes it exciting and unique in some respects.
I might be biased because HITI is my largest position by a wide margin, but that’s not why I’m saying this. Execution here has simply been exceptional. The numbers speak for themselves, the customer wins speak for themselves, and the pace of announcements speaks for itself.
Every analyst covering the company has a Buy rating
Canaccord Genuity → Buy, Target $US 5.50
Haywood → Buy, Target $US 5.90
Roth → Buy, target $US 5.00
TD Cowen → Buy, target $6.5 CAD
ATB CAPITAL Target 7$CAD
u/WilliamBlack97AI — 9 days ago
Nextech3D.ai Delivers Breakout Quarter
+216% Revenue Growth
91% Profit Margins
Operating Loss Collapses 96%
Gross profit up 275% YoY
AI Platform Inflection Point Is Here
Nextech3D today reported blowout Q4 and full-year audited results, confirming the Company has officially entered a powerful new AI-driven growth cycle.
THE INFLECTION POINT
- Revenue exploded +216% YoY — strongest quarter in Company history
- Gross margins surged to 91%+ — clear proof of software transition
- Operating loss collapsed 96% — massive operating leverage kicking in
- Gross profit up 275% YoY — scaling profitability now underway
This is not incremental progress — this is a fundamental business transformation.
Q4 2026: BREAKOUT PERFORMANCE
Nextech3D.ai delivered a true breakout quarter, signaling the start of a high-margin, scalable growth engine powered by AI.
- Revenue: $966K (+216% YoY)
- Gross Profit: $885K (+275% YoY)
- Gross Margin: 91.6% (vs. 77.2%)
- Operating Loss: $(263K) — down from $(7.21M)
- Net Loss: $(992K) vs. $(7.25M)
Translation: explosive growth + dramatically reduced burn = operating leverage inflection
FULL-YEAR FY2026: TOTAL TRANSFORMATION
- Revenue: $2.13M
- Gross Profit: $1.94M
- Gross Margin: 91.2% (vs. 63.6%)
- Cost of Sales: ↓ 85% YoY
- Operating Loss: ↓ 80% to $(2. 78M)
- Net Loss: ↓ 77% to $(3.23M)
The Company has completely reset its cost structure and is now operating as a high-margin AI software platform—not a services business.
CEO COMMENTARY – MOMENTUM IS ACCELERATING
“We delivered a breakout quarter, with revenue up 216% and margins exceeding 91%, proving our transition to a software-led, AI-driven business is working,” said CEO Evan Gappelberg.
“Our cost structure has been radically transformed, with cost of sales down 85% and operating loss reduced by 80%. This is a scalable, capital-efficient platform.”
“Q4 marks a clear inflection point as we enter fiscal 2027 with expanding margins, accelerating growth, and increasing adoption of our AI platform.”
WHY THIS MATTERS - THE BIG PICTURE
Nextech3D.ai is now positioned as a pure-play AI platform with:
✅ 90%+ recurring-style margins
✅ Massive operating leverage potential
✅ Lower fixed cost base
✅ Scalable SaaS economics kicking in
This is exactly the profile the market re-rates.
WHAT’S NEXT: FY2027 GROWTH DRIVERS
- Expansion of AI-powered product suite
- Increasing enterprise adoption
- Continued margin expansion
- Scaling revenue on a now-efficient cost base
Management believes the Company is entering a sustained growth phase with expanding margins and improving profitability.
BOTTOM LINE
The turnaround is complete.
The AI model is validated.
The operating leverage is here.
Nextech3D.ai is now positioned for accelerating revenue growth, expanding margins, and a potential market re-rating as a high-margin AI platform.
Evan Gappelberg
Chief Executive Officer
Nextech3D.ai
(CSE: NTAR | OTCQB: NEXCF | FSE: 1SS)
u/WilliamBlack97AI — 11 days ago
▲ 9 r/Nextech3Dai
$NEXCF: Record revenues across every corporate metric.
NTAR $NEXCF: Q4 Gross Margins hit a massive 91.33%! Elite tech metrics.
Just calculated the Q4 numbers for the 3 months ended March 31, 2026:
Total Revenue: $939,401.
Cost of Sales: ($81,421)
Gross Profit: $857,980.
Gross Profit Margin: 91.33%
A 91%+ gross margin is absolute top-tier for any software play. Over 91 cents of every dollar goes straight toward scalability and growth.
With margins this high and massive enterprise wins like ServiceNow and Capital One stacking up, the operating leverage is real.
Evan and the CFO go live today (Thursday, June 25th) at 4:30 PM EST to walk through the audited full-year financials. Do not miss this stream. 📈
DYOR.
u/WilliamBlack97AI — 11 days ago
▲ 26 r/HighTideInc
UK Medical Cannabis Imports and Product Availability Double, Market Could Near £400 Million in 2026, Finds Report
By 2030, the firm expects the market to grow to roughly £935 million
u/WilliamBlack97AI — 12 days ago
▲ 1 r/WSBAfterHours
Q2 Earnings call summary HITI Long term position
SUMMARY :
Despite the seasonally weaker quarter, it was the company's best quarter, which speaks volumes about HITI's increased operating efficiency.
Gms on medical cannabis 27%
Key Strengths of High Tide's Q2 FY2026
1. Strong Revenue Growth
- Record revenue of CAD $179.3 million.
- Approximately 30% year-over-year growth, representing one of the strongest growth rates in recent quarters.
2. Accelerating EBITDA Growth
- Record Adjusted EBITDA of CAD $13.9 million.
- EBITDA increased by approximately 73% year over year, significantly outpacing revenue growth, which indicates improving operating leverage and efficiency.
3. Positive Net Income
- The company reported positive net income and positive earnings per share (EPS).
- In the cannabis industry, profitability remains a major challenge for many companies, making High Tide's continued profitability particularly noteworthy.
- Management expects sustainable NET INCOME
4. Positive Free Cash Flow
- High Tide generated positive free cash flow and strong operating cash flow.
- This reduces the need to raise capital through equity issuances, helping to limit shareholder dilution.
5. Germany Continues to Exceed Expectations
- German subsidiary Remexian Pharma GmbH generated a record CAD $31.6 million in revenue.
- Gross margin improved to 27%.
- Management stated that several internal targets were achieved roughly 90 days ahead of schedule.
6. Rapid Expansion of the Customer Base
- The Cabana Club loyalty program surpassed 2.65 million members, up 39% year over year.
- ELITE memberships exceeded 178,000, up 84% year over year.
- This growing membership ecosystem strengthens customer loyalty, improves data analytics capabilities, and enhances High Tide's competitive advantage in retail.
- The stated goal is to exceed 1 million elite members in the long term.
7. Significant Banking Support
- The company secured a new credit facility of up to CAD $40 million from Bank of Montreal.
- Access to financing from a major Canadian bank is an important signal of financial credibility and stability in the cannabis sector.
- This has led to an increase in institutional interest in the stock which will be reflected as the company's fundamentals continue to improve.
8. Market Leadership
- High Tide continues to hold approximately 12% of the Canadian cannabis retail market in the provinces where it operates.
- The company is also steadily gaining market share in the German medical cannabis market.
- Raj is targeting 20% market share in Germany and I personally believe 30% is achievable in the long term for several reasons.
Most Bullish Takeaways
If I had to identify nine most bullish developments from the quarter, they would be:
- 73% growth in Adjusted EBITDA, demonstrating strong operational execution.
- Remexian's 27% gross margin, showing that the German business is scaling successfully and profitably.
- The new CAD $40 million credit facility, which provides growth capital without diluting shareholders.
- SNDL will have to sell some of its assets because it has violated regulations for years, and I wouldn't be surprised if it had to pay a hefty fine for breaking the law for so long. These assets will be carefully evaluated by Hiti for purchase.
- Possible increase in the cap in Ontario from 150->300 which Raj calls "a dream come true" bringing the number of canna cabana shops +500, but we'll have to see how things evolve
- The medical branch is growing throughout Europe, a constantly growing market, where Raj intends to be the leader in every country in which it operates (Germany, UK to follow).
- GMS have reached an all-time high. Raj states that due to competition, they will shrink slightly in the medium term in order to gain market share, but thanks to initiatives such as increasing ELITE/WHITE LABEL inventory from the current 2% to 25%, GMS will exceed 30% in the long term, also driven by Remexian's improved efficiency.
- Raj has stated his intention to enter the US, but for now he's focused on the European medical market and I support that.
- He says there's no rush to pursue multiple objectives at once, but rather to focus on one market at a time, strengthen its position by positioning itself as a leader, and move on to the next.
Together, these results suggest that High Tide is evolving from a pure growth story into a profitable growth company, a transition that investors often reward with higher valuation multiples over time.
HITI is becoming the definition of non-stop execution and deserves more credit for this. Remexian's goal is clear: gain more market share to satisfy this insatiable and ever-growing demand, in order to reach 20-30% market share in the long term and then achieve pricing determination with a consequent increase in GMS and profitability.
Still think HITI is vastly undiscovered.
Despite an increase in CAPEX linked to the expansion, the company continues to generate FCF+ and expects to increase net income thanks to ongoing synergies.
Raj is carefully evaluating expansion into another jurisdiction (UK), choosing the right partner for the long term.
This looks more like short-term noise than a deterioration in fundamentals. Remexian’s expansion in Germany and the economies of scale enjoyed by Canna Cabana represent genuine, differentiating competitive advantages. As long as management continues to pursue its market share targets and secure future pricing power, the valuation gap should gradually narrow. Investing in HITI will certainly be volatile, but the current fundamentals are much healthier than the stock price suggests. What's needed is patience and faith in the story.
The UK is the European market that excites him the most.
The UK medical market appears more interesting than the German one because High Tide could own the entire chain (from production directly to the patient). This is the medical system in which it is structured, which makes it exciting and unique in some respects.
I might be biased because HITI is my largest position by a wide margin, but that’s not why I’m saying this. Execution here has simply been exceptional. The numbers speak for themselves, the customer wins speak for themselves, and the pace of announcements speaks for itself.
Every analyst covering the company has a Buy rating
Canaccord Genuity → Buy, Target $US 5.50
Haywood → Buy, Target $US 5.90
Roth → Buy, target $US 5.00
TD Cowen → Buy, target $6.5 CAD
ATB CAPITAL Target 7$CAD
company presentation
https://hightideinc.com/presentation/
Long term
u/WilliamBlack97AI — 15 days ago
Q2 Earnings call summary HITI Long term position
SUMMARY :
Despite the seasonally weaker quarter, it was the company's best quarter, which speaks volumes about HITI's increased operating efficiency.
Gms on medical cannabis 27%
Key Strengths of High Tide's Q2 FY2026
1. Strong Revenue Growth
- Record revenue of CAD $179.3 million.
- Approximately 30% year-over-year growth, representing one of the strongest growth rates in recent quarters.
2. Accelerating EBITDA Growth
- Record Adjusted EBITDA of CAD $13.9 million.
- EBITDA increased by approximately 73% year over year, significantly outpacing revenue growth, which indicates improving operating leverage and efficiency.
3. Positive Net Income
- The company reported positive net income and positive earnings per share (EPS).
- In the cannabis industry, profitability remains a major challenge for many companies, making High Tide's continued profitability particularly noteworthy.
- Management expects sustainable NET INCOME
4. Positive Free Cash Flow
- High Tide generated positive free cash flow and strong operating cash flow.
- This reduces the need to raise capital through equity issuances, helping to limit shareholder dilution.
5. Germany Continues to Exceed Expectations
- German subsidiary Remexian Pharma GmbH generated a record CAD $31.6 million in revenue.
- Gross margin improved to 27%.
- Management stated that several internal targets were achieved roughly 90 days ahead of schedule.
6. Rapid Expansion of the Customer Base
- The Cabana Club loyalty program surpassed 2.65 million members, up 39% year over year.
- ELITE memberships exceeded 178,000, up 84% year over year.
- This growing membership ecosystem strengthens customer loyalty, improves data analytics capabilities, and enhances High Tide's competitive advantage in retail.
- The stated goal is to exceed 1 million elite members in the long term.
7. Significant Banking Support
- The company secured a new credit facility of up to CAD $40 million from Bank of Montreal.
- Access to financing from a major Canadian bank is an important signal of financial credibility and stability in the cannabis sector.
- This has led to an increase in institutional interest in the stock which will be reflected as the company's fundamentals continue to improve.
8. Market Leadership
- High Tide continues to hold approximately 12% of the Canadian cannabis retail market in the provinces where it operates.
- The company is also steadily gaining market share in the German medical cannabis market.
- Raj is targeting 20% market share in Germany and I personally believe 30% is achievable in the long term for several reasons.
Most Bullish Takeaways
If I had to identify nine most bullish developments from the quarter, they would be:
- 73% growth in Adjusted EBITDA, demonstrating strong operational execution.
- Remexian's 27% gross margin, showing that the German business is scaling successfully and profitably.
- The new CAD $40 million credit facility, which provides growth capital without diluting shareholders.
- SNDL will have to sell some of its assets because it has violated regulations for years, and I wouldn't be surprised if it had to pay a hefty fine for breaking the law for so long. These assets will be carefully evaluated by Hiti for purchase.
- Possible increase in the cap in Ontario from 150->300 which Raj calls "a dream come true" bringing the number of canna cabana shops +500, but we'll have to see how things evolve
- The medical branch is growing throughout Europe, a constantly growing market, where Raj intends to be the leader in every country in which it operates (Germany, UK to follow).
- GMS have reached an all-time high. Raj states that due to competition, they will shrink slightly in the medium term in order to gain market share, but thanks to initiatives such as increasing ELITE/WHITE LABEL inventory from the current 2% to 25%, GMS will exceed 30% in the long term, also driven by Remexian's improved efficiency.
- Raj has stated his intention to enter the US, but for now he's focused on the European medical market and I support that.
- He says there's no rush to pursue multiple objectives at once, but rather to focus on one market at a time, strengthen its position by positioning itself as a leader, and move on to the next.
Together, these results suggest that High Tide is evolving from a pure growth story into a profitable growth company, a transition that investors often reward with higher valuation multiples over time.
HITI is becoming the definition of non-stop execution and deserves more credit for this. Remexian's goal is clear: gain more market share to satisfy this insatiable and ever-growing demand, in order to reach 20-30% market share in the long term and then achieve pricing determination with a consequent increase in GMS and profitability.
Still think HITI is vastly undiscovered.
Despite an increase in CAPEX linked to the expansion, the company continues to generate FCF+ and expects to increase net income thanks to ongoing synergies.
Raj is carefully evaluating expansion into another jurisdiction (UK), choosing the right partner for the long term.
This looks more like short-term noise than a deterioration in fundamentals. Remexian’s expansion in Germany and the economies of scale enjoyed by Canna Cabana represent genuine, differentiating competitive advantages. As long as management continues to pursue its market share targets and secure future pricing power, the valuation gap should gradually narrow. Investing in HITI will certainly be volatile, but the current fundamentals are much healthier than the stock price suggests. What's needed is patience and faith in the story.
The UK is the European market that excites him the most.
The UK medical market appears more interesting than the German one because High Tide could own the entire chain (from production directly to the patient). This is the medical system in which it is structured, which makes it exciting and unique in some respects.
I might be biased because HITI is my largest position by a wide margin, but that’s not why I’m saying this. Execution here has simply been exceptional. The numbers speak for themselves, the customer wins speak for themselves, and the pace of announcements speaks for itself.
Every analyst covering the company has a Buy rating
Canaccord Genuity → Buy, Target $US 5.50
Haywood → Buy, Target $US 5.90
Roth → Buy, target $US 5.00
TD Cowen → Buy, target $6.5 CAD
ATB CAPITAL Target 7$CAD
company presentation
https://hightideinc.com/presentation/
Long term
u/WilliamBlack97AI — 15 days ago
Q2 Earnings call summary HITI Long term position
SUMMARY :
Despite the seasonally weaker quarter, it was the company's best quarter, which speaks volumes about HITI's increased operating efficiency.
Gms on medical cannabis 27%
Key Strengths of High Tide's Q2 FY2026
1. Strong Revenue Growth
- Record revenue of CAD $179.3 million.
- Approximately 30% year-over-year growth, representing one of the strongest growth rates in recent quarters.
2. Accelerating EBITDA Growth
- Record Adjusted EBITDA of CAD $13.9 million.
- EBITDA increased by approximately 73% year over year, significantly outpacing revenue growth, which indicates improving operating leverage and efficiency.
3. Positive Net Income
- The company reported positive net income and positive earnings per share (EPS).
- In the cannabis industry, profitability remains a major challenge for many companies, making High Tide's continued profitability particularly noteworthy.
- Management expects sustainable NET INCOME
4. Positive Free Cash Flow
- High Tide generated positive free cash flow and strong operating cash flow.
- This reduces the need to raise capital through equity issuances, helping to limit shareholder dilution.
5. Germany Continues to Exceed Expectations
- German subsidiary Remexian Pharma GmbH generated a record CAD $31.6 million in revenue.
- Gross margin improved to 27%.
- Management stated that several internal targets were achieved roughly 90 days ahead of schedule.
6. Rapid Expansion of the Customer Base
- The Cabana Club loyalty program surpassed 2.65 million members, up 39% year over year.
- ELITE memberships exceeded 178,000, up 84% year over year.
- This growing membership ecosystem strengthens customer loyalty, improves data analytics capabilities, and enhances High Tide's competitive advantage in retail.
- The stated goal is to exceed 1 million elite members in the long term.
7. Significant Banking Support
- The company secured a new credit facility of up to CAD $40 million from Bank of Montreal.
- Access to financing from a major Canadian bank is an important signal of financial credibility and stability in the cannabis sector.
- This has led to an increase in institutional interest in the stock which will be reflected as the company's fundamentals continue to improve.
8. Market Leadership
- High Tide continues to hold approximately 12% of the Canadian cannabis retail market in the provinces where it operates.
- The company is also steadily gaining market share in the German medical cannabis market.
- Raj is targeting 20% market share in Germany and I personally believe 30% is achievable in the long term for several reasons.
Most Bullish Takeaways
If I had to identify nine most bullish developments from the quarter, they would be:
- 73% growth in Adjusted EBITDA, demonstrating strong operational execution.
- Remexian's 27% gross margin, showing that the German business is scaling successfully and profitably.
- The new CAD $40 million credit facility, which provides growth capital without diluting shareholders.
- SNDL will have to sell some of its assets because it has violated regulations for years, and I wouldn't be surprised if it had to pay a hefty fine for breaking the law for so long. These assets will be carefully evaluated by Hiti for purchase.
- Possible increase in the cap in Ontario from 150->300 which Raj calls "a dream come true" bringing the number of canna cabana shops +500, but we'll have to see how things evolve
- The medical branch is growing throughout Europe, a constantly growing market, where Raj intends to be the leader in every country in which it operates (Germany, UK to follow).
- GMS have reached an all-time high. Raj states that due to competition, they will shrink slightly in the medium term in order to gain market share, but thanks to initiatives such as increasing ELITE/WHITE LABEL inventory from the current 2% to 25%, GMS will exceed 30% in the long term, also driven by Remexian's improved efficiency.
- Raj has stated his intention to enter the US, but for now he's focused on the European medical market and I support that.
- He says there's no rush to pursue multiple objectives at once, but rather to focus on one market at a time, strengthen its position by positioning itself as a leader, and move on to the next.
Together, these results suggest that High Tide is evolving from a pure growth story into a profitable growth company, a transition that investors often reward with higher valuation multiples over time.
HITI is becoming the definition of non-stop execution and deserves more credit for this. Remexian's goal is clear: gain more market share to satisfy this insatiable and ever-growing demand, in order to reach 20-30% market share in the long term and then achieve pricing determination with a consequent increase in GMS and profitability.
Still think HITI is vastly undiscovered.
Despite an increase in CAPEX linked to the expansion, the company continues to generate FCF+ and expects to increase net income thanks to ongoing synergies.
Raj is carefully evaluating expansion into another jurisdiction (UK), choosing the right partner for the long term.
This looks more like short-term noise than a deterioration in fundamentals. Remexian’s expansion in Germany and the economies of scale enjoyed by Canna Cabana represent genuine, differentiating competitive advantages. As long as management continues to pursue its market share targets and secure future pricing power, the valuation gap should gradually narrow. Investing in HITI will certainly be volatile, but the current fundamentals are much healthier than the stock price suggests. What's needed is patience and faith in the story.
The UK is the European market that excites him the most.
The UK medical market appears more interesting than the German one because High Tide could own the entire chain (from production directly to the patient). This is the medical system in which it is structured, which makes it exciting and unique in some respects.
I might be biased because HITI is my largest position by a wide margin, but that’s not why I’m saying this. Execution here has simply been exceptional. The numbers speak for themselves, the customer wins speak for themselves, and the pace of announcements speaks for itself.
Every analyst covering the company has a Buy rating
Canaccord Genuity → Buy, Target $US 5.50
Haywood → Buy, Target $US 5.90
Roth → Buy, target $US 5.00
TD Cowen → Buy, target $6.5 CAD
ATB CAPITAL Target 7$CAD
company presentation
https://hightideinc.com/presentation/
Long term
u/WilliamBlack97AI — 12 days ago
Q2 Earnings call summary HITI Long term position
SUMMARY :
Despite the seasonally weaker quarter, it was the company's best quarter, which speaks volumes about HITI's increased operating efficiency.
Gms on medical cannabis 27%
Key Strengths of High Tide's Q2 FY2026
1. Strong Revenue Growth
- Record revenue of CAD $179.3 million.
- Approximately 30% year-over-year growth, representing one of the strongest growth rates in recent quarters.
2. Accelerating EBITDA Growth
- Record Adjusted EBITDA of CAD $13.9 million.
- EBITDA increased by approximately 73% year over year, significantly outpacing revenue growth, which indicates improving operating leverage and efficiency.
3. Positive Net Income
- The company reported positive net income and positive earnings per share (EPS).
- In the cannabis industry, profitability remains a major challenge for many companies, making High Tide's continued profitability particularly noteworthy.
- Management expects sustainable NET INCOME
4. Positive Free Cash Flow
- High Tide generated positive free cash flow and strong operating cash flow.
- This reduces the need to raise capital through equity issuances, helping to limit shareholder dilution.
5. Germany Continues to Exceed Expectations
- German subsidiary Remexian Pharma GmbH generated a record CAD $31.6 million in revenue.
- Gross margin improved to 27%.
- Management stated that several internal targets were achieved roughly 90 days ahead of schedule.
6. Rapid Expansion of the Customer Base
- The Cabana Club loyalty program surpassed 2.65 million members, up 39% year over year.
- ELITE memberships exceeded 178,000, up 84% year over year.
- This growing membership ecosystem strengthens customer loyalty, improves data analytics capabilities, and enhances High Tide's competitive advantage in retail.
- The stated goal is to exceed 1 million elite members in the long term.
7. Significant Banking Support
- The company secured a new credit facility of up to CAD $40 million from Bank of Montreal.
- Access to financing from a major Canadian bank is an important signal of financial credibility and stability in the cannabis sector.
- This has led to an increase in institutional interest in the stock which will be reflected as the company's fundamentals continue to improve.
8. Market Leadership
- High Tide continues to hold approximately 12% of the Canadian cannabis retail market in the provinces where it operates.
- The company is also steadily gaining market share in the German medical cannabis market.
- Raj is targeting 20% market share in Germany and I personally believe 30% is achievable in the long term for several reasons.
Most Bullish Takeaways
If I had to identify nine most bullish developments from the quarter, they would be:
- 73% growth in Adjusted EBITDA, demonstrating strong operational execution.
- Remexian's 27% gross margin, showing that the German business is scaling successfully and profitably.
- The new CAD $40 million credit facility, which provides growth capital without diluting shareholders.
- SNDL will have to sell some of its assets because it has violated regulations for years, and I wouldn't be surprised if it had to pay a hefty fine for breaking the law for so long. These assets will be carefully evaluated by Hiti for purchase.
- Possible increase in the cap in Ontario from 150->300 which Raj calls "a dream come true" bringing the number of canna cabana shops +500, but we'll have to see how things evolve
- The medical branch is growing throughout Europe, a constantly growing market, where Raj intends to be the leader in every country in which it operates (Germany, UK to follow).
- GMS have reached an all-time high. Raj states that due to competition, they will shrink slightly in the medium term in order to gain market share, but thanks to initiatives such as increasing ELITE/WHITE LABEL inventory from the current 2% to 25%, GMS will exceed 30% in the long term, also driven by Remexian's improved efficiency.
- Raj has stated his intention to enter the US, but for now he's focused on the European medical market and I support that.
- He says there's no rush to pursue multiple objectives at once, but rather to focus on one market at a time, strengthen its position by positioning itself as a leader, and move on to the next.
Together, these results suggest that High Tide is evolving from a pure growth story into a profitable growth company, a transition that investors often reward with higher valuation multiples over time.
HITI is becoming the definition of non-stop execution and deserves more credit for this. Remexian's goal is clear: gain more market share to satisfy this insatiable and ever-growing demand, in order to reach 20-30% market share in the long term and then achieve pricing determination with a consequent increase in GMS and profitability.
Still think HITI is vastly undiscovered.
Despite an increase in CAPEX linked to the expansion, the company continues to generate FCF+ and expects to increase net income thanks to ongoing synergies.
Raj is carefully evaluating expansion into another jurisdiction (UK), choosing the right partner for the long term.
This looks more like short-term noise than a deterioration in fundamentals. Remexian’s expansion in Germany and the economies of scale enjoyed by Canna Cabana represent genuine, differentiating competitive advantages. As long as management continues to pursue its market share targets and secure future pricing power, the valuation gap should gradually narrow. Investing in HITI will certainly be volatile, but the current fundamentals are much healthier than the stock price suggests. What's needed is patience and faith in the story.
The UK is the European market that excites him the most.
The UK medical market appears more interesting than the German one because High Tide could own the entire chain (from production directly to the patient). This is the medical system in which it is structured, which makes it exciting and unique in some respects.
I might be biased because HITI is my largest position by a wide margin, but that’s not why I’m saying this. Execution here has simply been exceptional. The numbers speak for themselves, the customer wins speak for themselves, and the pace of announcements speaks for itself.
Every analyst covering the company has a Buy rating
Canaccord Genuity → Buy, Target $US 5.50
Haywood → Buy, Target $US 5.90
Roth → Buy, target $US 5.00
TD Cowen → Buy, target $6.5 CAD
ATB CAPITAL Target 7$CAD
company presentation
https://hightideinc.com/presentation/
Long term
u/WilliamBlack97AI — 15 days ago
▲ 1 r/pennystocks
Q2 Earnings call summary HITI Long term position
SUMMARY :
Despite the seasonally weaker quarter, it was the company's best quarter, which speaks volumes about HITI's increased operating efficiency.
Gms on medical cannabis 27%
Key Strengths of High Tide's Q2 FY2026
1. Strong Revenue Growth
- Record revenue of CAD $179.3 million.
- Approximately 30% year-over-year growth, representing one of the strongest growth rates in recent quarters.
2. Accelerating EBITDA Growth
- Record Adjusted EBITDA of CAD $13.9 million.
- EBITDA increased by approximately 73% year over year, significantly outpacing revenue growth, which indicates improving operating leverage and efficiency.
3. Positive Net Income
- The company reported positive net income and positive earnings per share (EPS).
- In the cannabis industry, profitability remains a major challenge for many companies, making High Tide's continued profitability particularly noteworthy.
- Management expects sustainable NET INCOME
4. Positive Free Cash Flow
- High Tide generated positive free cash flow and strong operating cash flow.
- This reduces the need to raise capital through equity issuances, helping to limit shareholder dilution.
5. Germany Continues to Exceed Expectations
- German subsidiary Remexian Pharma GmbH generated a record CAD $31.6 million in revenue.
- Gross margin improved to 27%.
- Management stated that several internal targets were achieved roughly 90 days ahead of schedule.
6. Rapid Expansion of the Customer Base
- The Cabana Club loyalty program surpassed 2.65 million members, up 39% year over year.
- ELITE memberships exceeded 178,000, up 84% year over year.
- This growing membership ecosystem strengthens customer loyalty, improves data analytics capabilities, and enhances High Tide's competitive advantage in retail.
- The stated goal is to exceed 1 million elite members in the long term.
7. Significant Banking Support
- The company secured a new credit facility of up to CAD $40 million from Bank of Montreal.
- Access to financing from a major Canadian bank is an important signal of financial credibility and stability in the cannabis sector.
- This has led to an increase in institutional interest in the stock which will be reflected as the company's fundamentals continue to improve.
8. Market Leadership
- High Tide continues to hold approximately 12% of the Canadian cannabis retail market in the provinces where it operates.
- The company is also steadily gaining market share in the German medical cannabis market.
- Raj is targeting 20% market share in Germany and I personally believe 30% is achievable in the long term for several reasons.
Most Bullish Takeaways
If I had to identify nine most bullish developments from the quarter, they would be:
- 73% growth in Adjusted EBITDA, demonstrating strong operational execution.
- Remexian's 27% gross margin, showing that the German business is scaling successfully and profitably.
- The new CAD $40 million credit facility, which provides growth capital without diluting shareholders.
- SNDL will have to sell some of its assets because it has violated regulations for years, and I wouldn't be surprised if it had to pay a hefty fine for breaking the law for so long. These assets will be carefully evaluated by Hiti for purchase.
- Possible increase in the cap in Ontario from 150->300 which Raj calls "a dream come true" bringing the number of canna cabana shops +500, but we'll have to see how things evolve
- The medical branch is growing throughout Europe, a constantly growing market, where Raj intends to be the leader in every country in which it operates (Germany, UK to follow).
- GMS have reached an all-time high. Raj states that due to competition, they will shrink slightly in the medium term in order to gain market share, but thanks to initiatives such as increasing ELITE/WHITE LABEL inventory from the current 2% to 25%, GMS will exceed 30% in the long term, also driven by Remexian's improved efficiency.
- Raj has stated his intention to enter the US, but for now he's focused on the European medical market and I support that.
- He says there's no rush to pursue multiple objectives at once, but rather to focus on one market at a time, strengthen its position by positioning itself as a leader, and move on to the next.
Together, these results suggest that High Tide is evolving from a pure growth story into a profitable growth company, a transition that investors often reward with higher valuation multiples over time.
HITI is becoming the definition of non-stop execution and deserves more credit for this. Remexian's goal is clear: gain more market share to satisfy this insatiable and ever-growing demand, in order to reach 20-30% market share in the long term and then achieve pricing determination with a consequent increase in GMS and profitability.
Still think HITI is vastly undiscovered.
Despite an increase in CAPEX linked to the expansion, the company continues to generate FCF+ and expects to increase net income thanks to ongoing synergies.
Raj is carefully evaluating expansion into another jurisdiction (UK), choosing the right partner for the long term.
This looks more like short-term noise than a deterioration in fundamentals. Remexian’s expansion in Germany and the economies of scale enjoyed by Canna Cabana represent genuine, differentiating competitive advantages. As long as management continues to pursue its market share targets and secure future pricing power, the valuation gap should gradually narrow. Investing in HITI will certainly be volatile, but the current fundamentals are much healthier than the stock price suggests. What's needed is patience and faith in the story.
The UK is the European market that excites him the most.
The UK medical market appears more interesting than the German one because High Tide could own the entire chain (from production directly to the patient). This is the medical system in which it is structured, which makes it exciting and unique in some respects.
I might be biased because HITI is my largest position by a wide margin, but that’s not why I’m saying this. Execution here has simply been exceptional. The numbers speak for themselves, the customer wins speak for themselves, and the pace of announcements speaks for itself.
Every analyst covering the company has a Buy rating
Canaccord Genuity → Buy, Target $US 5.50
Haywood → Buy, Target $US 5.90
Roth → Buy, target $US 5.00
TD Cowen → Buy, target $6.5 CAD
ATB CAPITAL Target 7$CAD
company presentation
https://hightideinc.com/presentation/
Long term
u/WilliamBlack97AI — 15 days ago
▲ 1 r/ValueInvesting
Q2 Earnings call summary HITI Long term position
SUMMARY :
Despite the seasonally weaker quarter, it was the company's best quarter, which speaks volumes about HITI's increased operating efficiency.
Gms on medical cannabis 27%
Key Strengths of High Tide's Q2 FY2026
1. Strong Revenue Growth
- Record revenue of CAD $179.3 million.
- Approximately 30% year-over-year growth, representing one of the strongest growth rates in recent quarters.
2. Accelerating EBITDA Growth
- Record Adjusted EBITDA of CAD $13.9 million.
- EBITDA increased by approximately 73% year over year, significantly outpacing revenue growth, which indicates improving operating leverage and efficiency.
3. Positive Net Income
- The company reported positive net income and positive earnings per share (EPS).
- In the cannabis industry, profitability remains a major challenge for many companies, making High Tide's continued profitability particularly noteworthy.
- Management expects sustainable NET INCOME
4. Positive Free Cash Flow
- High Tide generated positive free cash flow and strong operating cash flow.
- This reduces the need to raise capital through equity issuances, helping to limit shareholder dilution.
5. Germany Continues to Exceed Expectations
- German subsidiary Remexian Pharma GmbH generated a record CAD $31.6 million in revenue.
- Gross margin improved to 27%.
- Management stated that several internal targets were achieved roughly 90 days ahead of schedule.
6. Rapid Expansion of the Customer Base
- The Cabana Club loyalty program surpassed 2.65 million members, up 39% year over year.
- ELITE memberships exceeded 178,000, up 84% year over year.
- This growing membership ecosystem strengthens customer loyalty, improves data analytics capabilities, and enhances High Tide's competitive advantage in retail.
- The stated goal is to exceed 1 million elite members in the long term.
7. Significant Banking Support
- The company secured a new credit facility of up to CAD $40 million from Bank of Montreal.
- Access to financing from a major Canadian bank is an important signal of financial credibility and stability in the cannabis sector.
- This has led to an increase in institutional interest in the stock which will be reflected as the company's fundamentals continue to improve.
8. Market Leadership
- High Tide continues to hold approximately 12% of the Canadian cannabis retail market in the provinces where it operates.
- The company is also steadily gaining market share in the German medical cannabis market.
- Raj is targeting 20% market share in Germany and I personally believe 30% is achievable in the long term for several reasons.
Most Bullish Takeaways
If I had to identify nine most bullish developments from the quarter, they would be:
- 73% growth in Adjusted EBITDA, demonstrating strong operational execution.
- Remexian's 27% gross margin, showing that the German business is scaling successfully and profitably.
- The new CAD $40 million credit facility, which provides growth capital without diluting shareholders.
- SNDL will have to sell some of its assets because it has violated regulations for years, and I wouldn't be surprised if it had to pay a hefty fine for breaking the law for so long. These assets will be carefully evaluated by Hiti for purchase.
- Possible increase in the cap in Ontario from 150->300 which Raj calls "a dream come true" bringing the number of canna cabana shops +500, but we'll have to see how things evolve
- The medical branch is growing throughout Europe, a constantly growing market, where Raj intends to be the leader in every country in which it operates (Germany, UK to follow).
- GMS have reached an all-time high. Raj states that due to competition, they will shrink slightly in the medium term in order to gain market share, but thanks to initiatives such as increasing ELITE/WHITE LABEL inventory from the current 2% to 25%, GMS will exceed 30% in the long term, also driven by Remexian's improved efficiency.
- Raj has stated his intention to enter the US, but for now he's focused on the European medical market and I support that.
- He says there's no rush to pursue multiple objectives at once, but rather to focus on one market at a time, strengthen its position by positioning itself as a leader, and move on to the next.
Together, these results suggest that High Tide is evolving from a pure growth story into a profitable growth company, a transition that investors often reward with higher valuation multiples over time.
HITI is becoming the definition of non-stop execution and deserves more credit for this. Remexian's goal is clear: gain more market share to satisfy this insatiable and ever-growing demand, in order to reach 20-30% market share in the long term and then achieve pricing determination with a consequent increase in GMS and profitability.
Still think HITI is vastly undiscovered.
Despite an increase in CAPEX linked to the expansion, the company continues to generate FCF+ and expects to increase net income thanks to ongoing synergies.
Raj is carefully evaluating expansion into another jurisdiction (UK), choosing the right partner for the long term.
The UK is the European market that excites him the most.
The UK medical market appears more interesting than the German one because High Tide could own the entire chain (from production directly to the patient). This is the medical system in which it is structured, which makes it exciting and unique in some respects.
I might be biased because HITI is my largest position by a wide margin, but that’s not why I’m saying this. Execution here has simply been exceptional. The numbers speak for themselves, the customer wins speak for themselves, and the pace of announcements speaks for itself.
Every analyst covering the company has a Buy rating
Canaccord Genuity → Buy, Target $US 5.50
Haywood → Buy, Target $US 5.90
Roth → Buy, target $US 5.00
TD Cowen → Buy, target $6.5 CAD
ATB CAPITAL Target 7$CAD
Long term
u/WilliamBlack97AI — 15 days ago
Every analyst covering the company has a Buy rating
​
​
Canaccord Genuity → Buy, Target $US 5.50
​
Haywood → Buy, Target $US 5.90
​
Roth → Buy, target $US 5.00
​
TD Cowen → Buy, target $6.5 CAD
​
ATB CAPITAL Target 7$CAD
​
u/WilliamBlack97AI — 15 days ago
▲ 18 r/HighTideInc
Planet Microcap presentations
event.summitcast.comu/WilliamBlack97AI — 18 days ago